Ascentage Pharma's olverembatinib gets China NMPA's BTD to treat Philadelphia chromosome─positive acute lymphoblastic ...
Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, announced that its drug, olverembatinib, has been granted …